1. Home
  2. IHS vs MLYS Comparison

IHS vs MLYS Comparison

Compare IHS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IHS Holding Limited

IHS

IHS Holding Limited

HOLD

Current Price

$8.46

Market Cap

2.8B

ML Signal

HOLD

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$28.68

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IHS
MLYS
Founded
2001
2019
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.5B
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
IHS
MLYS
Price
$8.46
$28.68
Analyst Decision
Buy
Strong Buy
Analyst Count
6
7
Target Price
$8.29
$48.67
AVG Volume (30 Days)
1.3M
1.0M
Earning Date
05-19-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.26
N/A
Revenue Next Year
$7.87
N/A
P/E Ratio
$5.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.71
$22.30
52 Week High
$8.95
$47.65

Technical Indicators

Market Signals
Indicator
IHS
MLYS
Relative Strength Index (RSI) 59.04 56.53
Support Level $8.11 $25.56
Resistance Level $8.52 $31.26
Average True Range (ATR) 0.04 1.54
MACD 0.00 0.27
Stochastic Oscillator 60.00 56.63

Price Performance

Historical Comparison
IHS
MLYS

About IHS IHS Holding Limited

IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria and Sub-Saharan Africa. The majority of its revenue is derived from Nigeria.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: